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Microbial exopolysaccharides (EPS) have found outstanding medical applications
since the mid-20th century, with the first clinical trials on dextran solutions as
plasma expanders. Other EPS entered medicine firstly as conventional pharmaceutical
excipients (e.g., xanthan – as suspension stabilizer, or pullulan – in capsules and
oral care products). Polysaccharides, initially obtained from plant or animal sources,
became easily available for a wide range of applications, especially when they were
commercially produced by microbial fermentation. Alginates are used as anti-reflux,
dental impressions, or as matrix for tablets. Hyaluronic acid and derivatives are
used in surgery, arthritis treatment, or wound healing. Bacterial cellulose is applied
in wound dressings or scaffolds for tissue engineering. The development of drug
controlled-release systems and of micro- and nanoparticulated ones, has opened a
new era of medical applications for biopolymers. EPS and their derivatives are well-
suited potentially non-toxic, biodegradable drug carriers. Such systems concern rating
and targeting of controlled release. Their large area of applications is explained by
the available manifold series of derivatives, whose useful properties can be thereby
controlled. From matrix inclusion to conjugates, different systems have been designed
to solubilize, and to assure stable transport in the body, target accumulation and
variable rate-release of a drug substance. From controlled drug delivery, EPS potential
applications expanded to vaccine adjuvants and diagnostic imaging systems. Other
potential applications are related to the bioactive (immunomodulator, antitumor, antiviral)
characteristics of EPS. The numerous potential applications still wait to be developed
into commercial pharmaceuticals and medical devices. Based on previous and recent
results in important medical-pharmaceutical domains, one can undoubtedly state that
EPS medical applications have a broad future ahead.
Keywords: exopolysaccharides, medical applications, pharmaceuticals, perspectives
Introduction
Exopolysaccharides (EPS) are extracellular carbohydrate polymers produced and secreted by
microorganisms, which accumulate outside the cells. They are capable to be released into the
surrounding environment. Despite their monomeric composition, similar to well-known plant or
animal products, the EPS of diﬀerent microbial origin (bacteria and fungi) display a large variety
of structural combinations, which mediates them their unique properties. Microbial production
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shows several advantages over plant- or macro algae-derived
products, such as deﬁned and reproducible production
parameters to circumvent environmental inﬂuences, and
obtain a high quality of the ﬁnal product. Additionally, much
higher production titers can be obtained as compared to
polysaccharides extracted from plants.
Obtained from easily available, renewable resources,
biocompatible and apparently non-toxic, microbial EPS
have found a very large ﬁeld of applications, within which their
medical uses play an important role.
This review study aims at achieving a useful insight in
the domain, and at clearly distinguishing, in their historical
development, the current commercial applications of EPS –
oﬃcially acknowledged by worldwide accepted documents
of medical authorities, from their promising potential
applications – discussed in numerous publications. Such a
valuable knowledge was updated and organized according to
modern research directions in pharmaceutical science and
therapy. The presented data highlight a real outlook and
the necessary steps to enhance the eﬃciency and maximal
exploitation of the scientiﬁc progress recorded in the EPS ﬁeld
up to date.
Current Commercial Applications
Only a few microbial polysaccharides have found up to date
commercial applications. Amongst them, dextran, a neutral
polymer with α-(1−→6) and α-(1−→4) glucopyranosyl linkages
was, discovered in wine in mid of the 19th century. Dextran
could be considered the ﬁrst remarkable example for a microbial
EPS used in pharmaceutical applications (Nwodo et al., 2012). It
was used as a plasma volume expander for controlling wounds
shock since 1953 (Amspacher and Curreri, 1953; United States
Pharmacopeia [USP] –National Formulary [NF], 2012; European
Pharmacopeia [EP], 2014).
Further microbial EPS were employed in medical applications
as pharmaceutical excipients, after they were approved
as food additives. Xanthan, a bacterial branched anionic
heteropolysaccharide composed of a ﬁve sugar repeating unit
and diﬀerent amounts of acetate and pyruvate, was discovered
in 1950 (Born et al., 2002). Firstly it was used in large quantities
for enhanced oil recovery, and later on was approved as a
food additive in the USA (1969), by FAO/OMS (1974). In
Europe, xanthan was approved as food additive as E415 (198
2), with subsequent inclusion in US and EU pharmacopeias
(Born et al., 2002; United States Pharmacopeia [USP] –
National Formulary [NF], 2012; European Pharmacopeia
[EP], 2014). Similarly with food products, its properties as a
thickener and suspension stabilizer are useful in pharmaceutical
creams and suspensions and, recently, it has been used
as a drug controlled release carrier (Morris and Harding,
2009).
Alginate, originally obtained by extraction from seaweeds,
was discovered as a bacterial product in 1964, only diﬀering
from the seaweeds extraction product by the presence of
acetyl groups in the linear structure of β-(1−→4) mannuronic
and α-(1−→4) guluronic acid (Cyber Colloids Ltd.). This
anionic polysaccharide is a good disintegrating agent in tablets
(better than starch), a thickening and stabilizing agent in
pharmaceutical suspensions and emulsions, as well as an
antiacid stomach protector in capsules, as a sodium salt
(Mc Hugh, 1987). Bacterial alginate has been also employed
in cell microencapsulation, as microsphere vectors for drug
delivery (Mukherjee and Atala, 2005; Nwodo et al., 2012).
Five alginates were approved by FDA in 1973. Sodium
alginate found its monographs in US and EU pharmacopeias
(United States Pharmacopeia [USP] – National Formulary [NF],
2012; European Pharmacopeia [EP], 2014). Dental impression
compounds are based on alginate cold-setting gels. Alginate
ﬁbers can be used as wound dressings and bandages with
hemostatic properties, approved by FDA for human use
(Mc Hugh, 1987; Mukherjee and Atala, 2005; Nwodo et al.,
2012).
Gellan was discovered in 1978, as a bacterial anionic linear
heteropolysaccharide, with a repeating unit of α-rhamnose,
two residues of β-D-glucose and β-D-glucuronate. The native
form contains acyl (acetyl and glyceryl) substituents. The
acetyl groups can be easily removed by alkaline hydrolysis
to lower the acyl content if necessary. Nineteen oral, 16
ophthalmic and six nasal drug formulations with a very
large spectrum of therapeutic action are cited between 1993
and 2013 (Osmalek et al., 2014). Some of them became
commercial medical products, determining the inclusion
of low and high acyl forms of gellan in US pharmacopeia
(United States Pharmacopeia [USP] – National Formulary
[NF], 2012). Gellan has been FDA approved as a stabilizer
and thickener in food since 1990. A low acyl form is used
in solid dosage formulations, as a disintegration agent in
immediate release tablets, or, in higher concentrations,
as a matrix-forming excipient in sustained release, based
on its swelling behavior (Osmalek et al., 2014; CP Kelco).
In physiological ion concentrations, it forms in situ
strong gels (Hagerstrom, 2003; Osmalek et al., 2014). In
ophthalmic preparations, core gellan gum hydrogel showed
a prolonged contact time (ocular residence) and enhanced
bioavailability. Thus, ophthalmic controlled release anti-
glaucoma preparations containing commercial low acetyl
gellan are marketed under the trade name of Timoptic XE, or
Blocadren depot (Merck, Co.; Felt et al., 2002; Hagerstrom,
2003).
Pullulan seems to be the single commercially produced EPS
of fungal origin, with marketed pharmaceutical applications.
It was discovered in 1938, but mostly studied after its
description in 1959. This biopolymer is a neutral linear
homopolysaccharide, consisting almost of regularly repeating
α-(1−→4) – maltotriosyl units (3-D-glucopyranosyl) joined
through α-(1−→6). Its present applications as a pharmaceutical
ingredient are based on its distinct binding and ﬁlm-forming
properties, as well as on its strong oxygen impermeability. Such
properties make it very suitable for granulation and coating
tablets, non-animal capsules (Plantcaps-Capsugel, Inc.), oral
and wound care products (e.g., Listerine – Pﬁzer; Mocanu
et al., 2011b; Nagase Group; Tianjin SF–Bio). Approved ﬁrstly
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as a food ingredient in Japan (1976), USA-FDA (2002),
Europe, as E1204, and China (2006), pullulan has been lately
included in US, EU (United States Pharmacopeia [USP] –
National Formulary [NF], 2012; European Pharmacopeia [EP],
2014) and Japan Pharmacopeias (Japan Pharmacopeia [JP],
2011).
Hyaluronic acid was discovered in 1934 and with its
chemical structure established in the 1950s. Hyaluronic
acid is an anionic linear polysaccharide belonging to the
glycosaminoglycans, composed of disaccharide units consisting
of (1−→4) – β-linked-D-glucuronic acid and (1−→3) –
β-linked N-acetyl-D-glucosamine residues (Chong et al.,
2005; Kogan et al., 2007; Necas et al., 2008). As sodium
hyaluronate (hyaluronan), it plays important physiological
roles in living organisms, including the human body. Its
ﬁrst medical application, maintained until now, was as a
vitreous substitution/replacement during eye surgery in
the late 1950s (Necas et al., 2008). Originally obtained by
animal tissue extraction, especially from rooster coombs,
it is now produced by recombinant bacteria. The bacterial
product was ﬁrstly approved only for topical issues:
chronic, diﬃcult wound healing, e.g., Hyiodine, produced
by Contipro (Contipro Pharma), and cosmetic applications.
Lately, medical devices containing bacterial hyaluronan have
been approved for use in eye surgery and intraarticular
injections in osteoarthritis – e.g., Biolon – approved by
Medical Device Certiﬁcation-European Commission in
1995, FDA-USA in 1998, EUFLEXXA – approved by FDA-
USA in 2011 (both produced by Ferring Pharmaceuticals –
BTG), DUROLANE (EC-2004), produced by Bioventus
(Bioventus). A sustained-release formulation of recombinant
human growth hormone (SR-rhGH, DeclageTM, LG Life
Sciences, Korea) using sodium hyaluronate microparticles
was developed for administration on a weekly basis, being
approved by Korean FDA in 2007. Recent clinical studies
conﬁrmed its eﬃcacy and safety (Kim et al., 2014). Sodium
hyaluronate has got a monograph in European Pharmacopeia
(European Pharmacopeia [EP], 2014). A summary of the EPS
mentioned above, including their medical applications is given
in Table 1.
Potential Applications
An impressively large volume of publications have been
dedicated to the potential medical applications of EPS,
considering not only their number, but also their diversity.
The present paper aims at grouping such works in an accessible
TABLE 1 | Microbial exopolysaccharides with acknowledged commercial medical applications.
EPS Monomer composition Main producing
microorganism
Applications Reference
Bacterial
Dextran Glucose Leuconostoc
mesenteroides
Blood plasma volume expander
(controlling wound shock)
Amspacher and Curreri, 1953; Nwodo et al., 2012;
United States Pharmacopeia [USP] – National
Formulary [NF], 2012; European Pharmacopeia
[EP], 2014
Xanthan Glucose (2), mannose (2),
glucuronic acid, acetate,
pyruvate
Xanthomonas campestris Thickener, suspension stabilizer in
pharmaceutical creams and
suspensions Controlled release
carrier
Born et al., 2002; Morris and Harding, 2009; United
States Pharmacopeia [USP] – National Formulary
[NF], 2012; European Pharmacopeia [EP], 2014
Alginate Mannuronic acid, guluronic
acid, acetate
Azotobacter vinelandii,
Pseudomonas aeruginosa
Disintegrating agent in tablets;
thickener, stabilizer in
pharmaceutical suspensions and
emulsions; dental impressions;
antiacid (anti-reflux) stomach
protector; microspheres for drug
delivery; fibers in wound hemostatic
dressing and bandages
Mc Hugh, 1987; Mukherjee and Atala, 2005;
Nwodo et al., 2012; United States Pharmacopeia
[USP] – National Formulary [NF], 2012; European
Pharmacopeia [EP], 2014; Cyber Colloids Ltd.
Gellan Glucose, rhamnose,
glucuronic acid, glycerate,
acetate
Sphingomonas
paucimobilis (formerly
Pseudomonas elodea)
Excipient in oral, ophthalmic and
nasal drug formulations, for: tablet
disintegration, sustained/controlled
release
Felt et al., 2002; Hagerstrom, 2003; United States
Pharmacopeia [USP] – National Formulary [NF],
2012; Osmalek et al., 2014; CP Kelco
Hyaluronic
acid/hyaluronan
Glucuronic acid
N-acetyl-glucosamine
Streptococcus
equisimilis/zooepidemicus;
Bacillus subtilis
(recomb.Str. equisimilis)
Chronic, difficult wound healing;
osteoarthritis treatment
(intraarticular injection); eye surgery
(vitreous substitution/replacement)
Kogan et al., 2007; Necas et al., 2008; Food and
Drug Administration-Premarket Approval
Application [FDA-PMA], 2011; European
Pharmacopeia [EP], 2014; Bioventus; Contipro
Pharma
Fungal
Pullulan Maltotriose Aureobasidium pullulans Tablet granulation and coating,
binder, and oxygen impermeable
film forming, non-animal capsules,
oral, and wound care products
Japan Pharmacopeia [JP], 2011; Mocanu et al.,
2011b; United States Pharmacopeia [USP] –
National Formulary [NF], 2012; European
Pharmacopeia [EP], 2014; Nagase Group; Tianjin
SF–Bio
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manner, to obtain a relevant and suggestive image of the
ﬁeld.
Drug/Hydrogel Controlled Release Systems
Micro- and Nanosystems for Sustained Delivery
Polysaccharides and, among them, EPS, have become highly
promising materials in the ﬁeld of “intelligent drug delivery
systems” or “intelligent therapeutics” (Caldorrera-Moore and
Peppas, 2009; Patel et al., 2011). The ability of such hydrophilic
polymers to form hydrogels, cross-linked 3D network structures
retaining a large amount of water while remaining insoluble,
makes them very useful as drug carriers. Thus, as macro-
and especially nanoparticles, such gels can entrap drugs
or biomolecules into their inner structures and/or adsorb
the therapeutic molecules onto their external surfaces and
penetrate cells and tissue gaps to arrive at target organs.
Having reached them, the drug delivery systems can show
diﬀerent drug rate-release properties due to their various
characteristics, including bioadhesion, biodegradability, pH, ion
and/or temperature sensitivity. In this way, they can prolong
drug residence and, therefore, its therapeutically usable fraction,
thus increasing its bioavailability and permitting lower doses
with consequently reduced toxic eﬀects (Liu et al., 2008).
Natural polysaccharides have a large number of reactive
groups, a wide range of molecular weights and diﬀerent
chemical composition, leading to highly diverse structures and
properties; additionally, they are biodegradable, non-toxic and
safe.
Hydrogels with thermo-, pH-, and cation-sensitive
drug-delivery properties
Pullulan has been intensively studied as a drug carrier in
pharmaceutics, particularly because of its neutral nature with
nine hydroxyl groups on the repeating unit conferring to it a
special availability to chemical derivatization. By cross-linking
and grafting on the backbone, poly-(N-isopropyl-acrylamide)-
co-acrylamide and ether succinic carboxyl groups, thermo- and
pH-sensitive microspheres were obtained. With lysozyme as
the protein drug model, both simple and electrostatic (ionic)
entrapment and pH/thermo sensitive release were achieved
(Fundueanu et al., 2008). Pullulan/silver nanoparticles composite
nanospheres with controlled spherical structure showed to
enhance antibacterial activity (Kumar et al., 2012). Silver-
containing nanoparticles have been also obtained by partial
oxidation of pullulan (carboxylation; Coseri et al., 2015).
Carboxymethyl pullulan, grafted with polyether-amine, as the
thermo sensitive part of the copolymer, exhibited a sol-gel
transition at body temperature, assuring sustained drug-delivery
(Dulong et al., 2012). Such polymers, containing carboxymethyl
pullulan, cross-linked to thermo- and pH-sensitive hydrogels,
gradually retained the antioxidant biomolecules – lutein and
α-tocopherol – and showed scavenging activity (Mocanu
et al., 2012). In situ rapid cation-induced gelation of gellan
favored, the epithelial uptake (at a residence time shown
in vivo as long as 4 h), and transfer of a model substance
demonstrated the use of gellan as a promising strategy
for nasal drug delivery, thus avoiding a slow and reduced
absorption of some drugs by oral administration (Hagerstrom,
2003).
Amphiphilic EPS, as controlled delivery systems
Grafting of hydrophobic segments onto the hydrophilic
polymeric backbone leads to amphiphilic polymers which form
self-associate thermodynamically stable nanogel structures,
with an inner hydrophobic core. Stable in size over time,
such polymeric micelles have been recognized as promising
drug carriers, the hydrophobic core-shell structure being
able to trap hydrophobic drugs (Liu et al., 2008; Bataille
et al., 2011; Jiang et al., 2013). In this respect, the most cited
paper was an early work from 1993 on the self-assembly of
cholesteryl-bearing pullulan (CHP), forming stable hydrogel
nanoparticles, which represented the starting point for future
perspective drug-release complexes (Bataille et al., 2011). Thus,
self-aggregated nanoparticles of cholesterol-modiﬁed pullulan
with succinyl linkages were loaded with mitoxantrone (as
model anticancer) and exhibited sustained release (Yang et al.,
2010).
Other cross-linking microspheres obtained from
carboxymethyl pullulan became more adsorptive by their ionic
and hydrophobic aﬃnity for lysozyme. After hydrophobization
with palmitoyl the release rate was also controlled (Mocanu et al.,
2004).
Interpenetrating polymer networks (IPNs)
Interesting potential medical applications may be realized
by the hydrogels of polysaccharides. Such “smart” systems,
consisting of penetrating polymers at molecular scale, promise
to be perspective drug-carriers. Thus, interpenetrating polymer
network (IPN) microspheres of alginate and synthetic or natural
polymers showed entrapping and sustained release properties
of diﬀerent drug substances: anticancer 5-ﬂuorouracyl,
anti-inﬂammatory indomethacin, antibiotic gatiﬂoxacin,
anticoagulant heparin, NSAID sulidac, as well as intestinal
release of the poorly soluble anti-hypertensive pindolol
(Matricardi et al., 2013).
Beads of gellan gum/pectin mixture, obtained by ionotropic
gelation, using Al3+ as crosslinker, showed suitable entrapment
and mucoadhesive properties for enteric in vitro controlled
release of anti-inﬂammatory ketoprofen (Prezotti et al., 2014).
Poly (ε-caprolactone)-grafted dextran nanoparticles entrapped
and exhibited in vitro sustained release of amoxicillin antibiotic
(Saldias et al., 2015).
Steroid hormones, as important drug-substances, whose
administration may be improved by sustained delivery, are
almost absent in latest EPS research. Micro- and nanoparticles
containing such compounds in transdermal drug delivery
systems can avoid many of the side eﬀects associated with ﬁrst-
pass metabolism, gastrointestinal absorption and high plasma
levels after oral administration, reaching clinically signiﬁcant
concentrations at lower doses. Studies on their pharmacokinetics,
bioequivalence, local tolerance, and adhesion performance are
necessary.
Another suggestion involves grafted block copolymers of only
EPS, not considered in recently published research results.
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Drug-Targeting, Macromolecule, and Cell Carriers
Drug-targeting
Polysaccharide conjugates, especially the amphiphilic ones, with
diﬀerent hydrophobization degrees, showed particular binding
and penetrating features to cellular receptors, appearing as
promising drug-targeting carriers.
Thus, cholesteryl-pullulan nanoparticles can hydrophobically
interact with the beta oligomer forms of beta-amyloid,
signiﬁcantly reducing its toxicity, which appears as a possible
complementary approach in neurologic disorders with formation
of soluble toxic aggregates, e.g., in Alzheimer disease (Boridy
et al., 2009).
Anticancer drug-targeting
Self-assembled nanoparticles of carboxymethyl curdlan, a known
(1−→3)-β-glucan, hydrophobized by deoxycholic residues,
physically loaded with anticancer epirubicin, increased the drug
uptake in tumors and decreased it in kidney and heart on
tumor-bearing mice, showing a sustained release pattern and
a tumor volume reduced by 70% (Gao et al., 2010). Other
hydrophobized polysaccharide – bile acid conjugate (hyaluronic-
cholanic acid) nanoparticles showed a receptor-mediated in vitro
and in vivo preferential accumulation, in murine carcinoma
SCC7 cells (Choi et al., 2009). Hyaluronic acid-coated solid
lipid (freeze-dried) nanoparticles showed in vitro and in vivo a
receptor-mediated, sustained and targeted delivery of anticancer
vorinostat to SCC7 carcinoma, human breast adenocarcinoma
(MCF-7) and human lung epithelial adenocarcinoma (A549;
Tran et al., 2014).
Recently, a novel gellan nanohydrogel system was developed,
for simultaneously carrying two poorly water soluble drugs
(physically entrapped paclitaxel and chemically linked
prednisolone) to achieve target delivery of such anticancer
and anti-inﬂammatory drugs. Promising in vitro results –
induced by their synergistic eﬀect – on three types of cancer cells,
were noticed (D’Arrigo et al., 2014).
Transdermal drug delivery is an important pharmaceutical
alternative for drug-targeting in skin diseases. Hyaluronic acid
nanoemulsions showed an eﬃcient selective in vitro and in vivo
controlled-release of methylene-dioxycamptothecin, an inhibitor
of keloid dermal tumors (Gao et al., 2014).
Curcumin-loaded hydrogels of xanthan-plant galactomannan
mixture were eﬀective in skin-diseases, as anti-inﬂammatory and
antioxidant drugs, which may recommend them as a promising
alternative in the treatment of skin-cancer and psoriasis (Koop
et al., 2015).
Biolabile prodrug compounds (releasing the drug by micro
ﬂora enzymatic glycosidase hydrolysis of the gels selected
from dextran, pullulan, and alginates), or cross-linked dextran
hydrogels showed colon-speciﬁc drug delivery (Vandamme
et al., 2002). Another prodrug conjugate, the hyaluronic acid-
methotrexate, an anti-inﬂammatory substance, optimized the
treatment of osteoarthritis, showing in vivo eﬀect on rats
(Homma et al., 2010).
A very promising, still non-explored ﬁeld is the use of properly
functionalized EPS as drug-carriers, to cross the blood-brain
barrier for treating tumors or other neurological diseases.
Recombinant macromolecular biopharmaceuticals
Proteins, peptides, small-interfering RNA (siRNA), vaccines
and hormones – represent a rapidly growing class of modern
therapeutics, superior to small drugs for serious and deadly
diseases, as well as for diagnostics. However, they have diﬃculties
in crossing mucosal surfaces and biological membranes, due to
their susceptibility to lose the native structure and to be rapidly
cleared in the liver or other body tissues. Polymeric hydrogels
used as carriers could diminish their instability and improve
bioavailability, permitting other routes of administration, apart
from the frequently injectable: pulmonary, oral, nasal ones
(Ganguly et al., 2014).
In this respect, special importance is paid to insulin, a
long-term treatment drug of diabetes mellitus. Nanoparticles of
cholesterol-bearing pullulan preserved insulin from enzymatic
degradation, its activity being unchanged after i.v. injection
(Akiyoshi et al., 1998). Insulin was 85% electrostatically
associated to nanoparticles of dextran sulfate/chitosan, with
a 24 h sustained release in a simulated intestinal medium,
suggesting a possible oral delivery (Sarmento et al., 2006).
Vitamin B12-derivatives-coated dextran nanoparticles
encapsulated more than 65% insulin and demonstrated a
prolonged hypoglycemic action on diabetic mice and rats, after
oral administration (Chalasani et al., 2007).
Recombinant human growth hormone-Zn2+/dextran
nanoparticles preserved 99% of hormone bioactivity (Yuan et al.,
2012). Lysozyme, as a model protein, was highly retained and
well-released on pH and thermo sensitive (Poloxamer grafted)
carboxymethyl pullulan micro particles (Mocanu et al., 2011a).
The hyaluronic acid-gold nanoparticle/interferon α complex
showed target speciﬁcity and prolonged delivery in the murine
liver tissue, leading to superior immune responses than the
known interferon α preparation for the treatment of hepatitis
C virus infection (Lee et al., 2012). Nowadays, successful
non-interferon therapeutics diminishes the importance of such
systems.
Vaccines
Exopolysaccharide could be useful as antigen-carriers or as
antigens themselves in vaccine preparations. Tetanus toxoid
(anatoxin) was entrapped and eﬃciently released on Poloxamer
hydrophobized carboxymethyl pullulan micro particles (Mocanu
et al., 2011a). Intranasal immunization with alginate-tetanus
toxoid microparticles resulted in a strong immunoresponse in
rabbits. Esters of the hyaluronic acid loaded with hemagglutinin
inﬂuenza H1N1were also eﬀective after intranasal administration
in mice, rabbits, micro-pigs (Sharma et al., 2009). Curdlan
sulfate enhanced antigen-speciﬁc immunity in mice immunized
with human recombinant hepatitis B protein, appearing as
a promising vaccine adjuvant (Li et al., 2014). Puriﬁed by
ultraﬁltration, type B capsular polysaccharide produced by
Haemophilus inﬂuenzae, which was linked to a protein, became
a component of polyvalent vaccines against severe infections in
children (e.g., meningitis; Albani et al., 2015; De Oliveira Cintra
and Takagi, 2015).
As novel adjuvant systems, EPS could enhance vaccine-
induced protection, providing a strong tailored and immune
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response, especially targeting challenging pathogens, such
as new inﬂuenza pandemic strains (e.g., H1N1, parasites
(malaria), highly variable viruses (hepatitis C, AIDS), or resistant
mycobacteria (tuberculosis). Another direction is represented by
antigen-speciﬁc cancer immunotherapy, stimulating an immune
response to reject the tumor.
Gene delivery
Non-viral vectors, e.g., polymers, are preferred to deliver nucleic
acid materials, to improve the transport and avoid degradation
by lysosomal enzymes. Plasmid encapsulation in pullulan
nanoparticles demonstrated a successful internalization (Gupta
and Gupta, 2004). Cationic dextran derivative nanoparticles,
loaded with gene silencing siRNA, achieved an eﬀective
transfection in hepatoma Huh-7 cells, by association with a
photosensitizer (Raemdonck et al., 2010). The same genetic
material was also transferred by PEG-ylated dextran to Huh-
7 and A 431 human epithelial carcinoma cells (Naeye et al.,
2010). Cationic siRNA loaded 6-amino-deoxicurdlan eﬃciently
transfected human lung H727 and human colon HCT116
cancer cell lines, human leukemia monocyte THP-1 cell-derived
macrophages, as well as mouse primary and stem cells (Han
et al., 2015). Other gene-delivery studies, including pDNA with
EPS derivatives, mostly amino-modiﬁed, e.g., gellan, alginate,
schizophyllan and scleroglucan, fungal β-(1−→3)-glucans with
β-(1−→6)-glucose side chains, were also cited (Khan et al., 2012;
Zhang et al., 2013).
Using EPS as gene delivery vectors is a recent potential
application which should be conﬁrmed by in vivo studies, as
future research depends on gene therapy development in cancer.
Cell encapsulation
This technology is considered protecting transplanted cells
from hostile immune reactions of the body, assuring at the
same time the permeation of nutrients and secreted proteins.
The transplantation of encapsulated cells has been considered
a promising treatment for a variety of diseases (e.g., diabetes,
liver failure; Rokstad et al., 2014). To make able the 3D structure
of bacterial cellulose (BC) nanoﬁbers to form a cross-linked
alginate-based composite with improved mechanical and
chemical stability, BC, produced by Gluconacetobacter xylinus
fermentation, was oxidized at C-6 in the NaBr/NaClO/TEMPO
(tetramethyl-piperidine-1-oxyl) system as a catalyst. The
C-6-carboxyl-cellulose-sodium alginate beads successfully
encapsulated ﬁbroblast cells. Such composite is considered a
candidate to encapsulate cells forming islets to activate insulin
secretion (Park et al., 2015).
Obtaining encapsulated cells within a three-dimensional
hydrogel layer is considered as a new direction in microscale
tissue engineering (Evans et al., 2006).
Wound Healing and Tissue Engineering
Wound healing-skin repair
Bacterial cellulose
Bacterial cellulose is produced by bacterial fermentation with
controllable 3D structure, based on strains selection or cultivation
parameters (Lin et al., 2013). The resulting non-water soluble
nanoﬁbril network shows high similarity to that of collagen
and has an outstanding biocompatibility (Torres et al., 2012).
The applications of BC are in the ﬁeld of wound healing-
skin repair, as absorbent of exudates as well as permeable
material. Compared to plant cellulose, BC possesses a high
crystallinity, a high water absorption capacity, as well as high
resistance to microbial or enzymatic degradation. Its properties
as a wound healing and tissue engineering scaﬀold could
be diversiﬁed and improved according to speciﬁc aims, by
chemical derivatization or association of other synthetic, mineral
(e.g., hydroxyapatite) substances, biopolymers (e.g., hyaluronan,
alginate, gellan, carrageenan, chitosan, collagen, gelatin, elastin),
or cell-growth factors (Torres et al., 2012; Fu et al., 2013).
Clinical trials with BC-dressings on acute and chronic wounds
(e.g., diabetic foot ulcers) showed superior results than similar
dressings from plant-cellulose (Fu et al., 2013). BC-glycerin
membranes with a clinically proved moisturing eﬀect could
be relevant for dryness induced by skin diseases, such
as psoriasis and atopic dermatitis (Almeida et al., 2014).
Electrospun acetylated BC presented amore symmetric nanopore
structure than that of the casting ﬁlms, suitable for cell
integration and adhesion (Costa et al., 2012). Dressings with
hydrogels of BC/acrylic acid synthesized by electron beam-
irradiation accelerated burn wound healing in rats (Najwa et al.,
2014).
Tissue engineering
Heart tissue engineering aims at designing structures to support,
repair, replace, or enhance the function of injured or diseased
myocardial tissues, especially as caused by infarction. In this
respect, alginate, pullulan, dextran, hyaluronan have been
intensively studied (Silva et al., 2015). Photopolymerizable
hyaluronic acid-methacrylic anhydride (HA-MA) hydrogels
mimicked the extracellular matrix in heart valve applications
(Aravamudhan et al., 2014). Alginate-based hybrid copolymers
with poly(propylene) fumarate, morphologically modiﬁed
by covalent linking with acrylates, acquired improved
mechanical properties. One of them was described to
promote cardiomyoblast growth, recommending it for potential
applications in cardiac tissue engineering (Thankam and Muthu,
2014).
Schiﬀ-base formation between oxidized dextran (aldehyde)
and poly-L-lysine led to a potential bioadhesive in surgery
(Matsumura et al., 2014). Carboxymethyl pullulan-heparin
conjugates were developed and studied for tissue engineering
applications (Mishra et al., 2011). Electrospun gelatin nanoﬁbers
cross-linked with oxidized dextran (aldehyde) demonstrated
good scaﬀold properties for L-926 ﬁbroblasts (Jalaja et al.,
2014). Alginate scaﬀolds were eﬀective for chondrocyte culture
stem cells, as a promising solution for cartilage regeneration,
combating osteoarthritis and arthroplasty. If they contain
chitosan, calcium, or are impregnated with antibiotics, they
could enhance the antibacterial and wound healing eﬀect of
bandages (Ivanova et al., 2014). Alginate materials have been
successfully used in tissue-engineering of bioartiﬁcial pancreas,
bone, vasculature, and liver cell cultures (Aravamudhan et al.,
2014). Some new EPS produced by bacteria isolated from
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extreme marine environments showed promising properties for
tissue engineering in bone healing (Mancuso Nichols et al.,
2005).
In tissue engineering, special interest is paid to stem cells
and the design of bioactive nanopatterned scaﬀolds of diﬀerent
polymeric materials, including EPS, with speciﬁc ligands that
direct and enhance cell function and diﬀerentiation of embryonic
stem cells (Evans et al., 2006).
Diagnostics
Polysaccharide-coated nanoparticles used in diagnostics (e.g.,
quantum dots, magnetic materials, such as iron oxide) could
play a key role in medical imaging and also in theranostics
(diagnosis and therapy). Speciﬁc ligand groups could be attached
to the biopolymer, such as amino. Cholesterol pullulan modiﬁed
by amino groups showed a higher intensity of ﬂuorescence in
tumor cells, comparatively with conventional quantum-dots-
liposomes (Bataille et al., 2011; Mishra et al., 2011; Prajapati
et al., 2013). A complete platform of super paramagnetic iron
oxide nanoparticles with cross-linked dextran coating (CLIO) –
containing large series of multifunctional imaging agents for
diagnostic magnetic resonance (DMR), magnetic resonance
imaging (MRI), positron emission tomography (PET) imaging,
ﬂuorescence molecular tomography (FMT) – has been developed.
As a theranostic agent, CLIO could be used with a photosensitizer
in photodynamic therapy, killing atheroma cells in carotid
arteries through irradiation (Tassa et al., 2011). A theranostic
eﬀect was obtained with acetylated pullulan-coated magnetic
nanoparticles, killing 80% of the KB tumor cells by magnetic
ﬁeld-induced hyperthermia (Bataille et al., 2011; Mishra et al.,
2011).
Theranostic application of such diagnostics implies repeated
dose administration, depending essentially on the metabolism
and elimination of iron particles.
Bioactive EPS as Potential Therapeutics
Fungal β-Glucans
Some EPS showed biological activities which promote them
as potential therapeutics. A special interest in this view has
attracted β-glucans. Generally, the immunomodulation eﬀect of
β-glucans is due to their interactions with macrophage receptors,
activating these cells as basic eﬀectors in host defense against
bacteria, viruses, parasites, and tumor cells (Novak and Vetvicka,
2009). Therefore, from the early 90s on, the backbone of β-
(1−→3) glucans has been considered as essential for their
antitumor activity, based on the Sarcoma tumor inhibition
by sulfoalkyl-curdlan (Demleitner et al., 1992), as well as for
their immunopotentiating, antibacterial, or antiviral activity
(Kulicke et al., 1997). β-glucans have shown varying activity
against sarcomas, mammary cancer, some chemically induced
cancers, colon cancer, and some leukemia (Laroche andMichaud,
2007).
Schizo- and scleroglucans
The most important representatives of fungal beta-glucans
are schizophyllan (SPG) and scleroglucan (SG), neutral EPS
produced by Schizophyllum commune (Zhang et al., 2013)
and Sclerotium rolfsii, respectively (Survase et al., 2007). They
are composed by a β-(1−→3)-D-glucopyranose backbone
which is branched with a single β-(1−→6)-D-glucopyranose
residue at every third glucose unit. Single or associated with
chemotherapeutics, these EPS and their derivatives showed
promising antitumor (in sarcoma, carcinomas, bladder
tumor, ﬁbro sarcoma, mammary carcinoma, leukemia) and
immunopotentiator activities. SPG has been approved for
clinical studies in Japan (Daba and Ezeronye, 2003; Zhang et al.,
2013). SSG, produced by the Sclerotinia sclerotiorum fungus,
whose structure is similar to that of schizophyllan, yet more
branched (a glucose residue occurs at every two β-1, 3-glucosyl
units) showed antitumor activity on Sarcoma 180 in mice (Ohno
et al., 1986).
The β-(1−→3) backbone, as mentioned above, but the β-
(1−→6)-glycosidic linked branches structures, too, appear as
important for antitumor activity.
Botryosphaeran
Represents another β-(1−→3, 1−→6)-glucan (1−→3 backbone,
1−→6 branched glucose and gentiobiose) and is produced by
Botryosphaeria rhodina. Botryosphaeran showed anticlastogenic
activity in vivo (mice) after cyclophosphamide (Miranda
et al., 2008). It also exhibited antidiabetic (reducing plasma
glucose level in streptozocin-induced diabetic rats by 52%)
and hypocholesterolemic activities (total and LDL cholesterol
reduced until 27% in hyperlipidemic rats; Miranda-Nantes
et al., 2011). Chemical modiﬁcations increased biological activity
(Kagimura et al., 2015). The sulfonated derivative induced in vitro
a dose-dependent anticoagulant and antithrombotic activity
(Mendes et al., 2009).
Lasiodiplodan
Exopolysaccharide, a β-(1−→6)-D-glucan produced by
Lasiodiplodia theobromae, showed anti-proliferative activity
in breast cancer MCF-7 cells (Alves da Cunha et al., 2012),
whereas its sulfonated derivative exhibited anticoagulant and
antithrombotic activity similar to that of heparin (Vasconcelos
et al., 2013).
A hetero-EPS (mainly mannose, glucose, galactose, xylose)
produced in submerged cultivation of the Pycnoporus sanguineus
fungus exhibited in vitro antioxidant activity (Cao et al., 2014).
Similar results were obtained with a Hirsutella sp. fungus
(neutral EPS containing mannose, glucose, galactose), proving
the importance of the mannose content (Meng et al., 2015).
A fraction of α- and β-EPS (mainly composed of mannose,
glucose, and talose), produced in a submerged culture by the
Chinese medical fungus Inocutis tamaricis, exhibited in vitro
antioxidant and antitumor (Hep G2 cells) activities (Zheng et al.,
2014).
Antitumor activity of EPS is immune-mediated
(immunotherapy) by the activation of the T and B defender cells
against cancer cells. Although their action is slower than that of
traditional therapies (chemotherapy, radiation), it is nevertheless
speciﬁc, adaptable and durable. Thus, immunotherapeutic
EPS could be valuable prophylactic and synergic anticancer
agents.
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Bacterial EPS
Lactic bacterial EPS
One group of bioactive EPS is represented by those produced
by lactic bacteria (LAB). A 2-substituted β-(1−→3)-D-glucan
produced by Pediococcus parvulus 2,6 and a recombinant
Lactococcus lactis showed immunomodulation by human
macrophage activation in vitro, promoting the production of
anti-inﬂammatory cytokines (Notararigo et al., 2014). A similar
eﬀect was noticed with a neutral hetero-EPS (glucose, rhamnose,
galactose) produced by a Lactobacillus paraplantarum strain
in an in vitro study as a probiotic agent (good adherence to
intestinal mucosa; Nikolic et al., 2012). Other EPS of LAB species
(e.g., Weissella cibaria), isolated from the gastrointestinal tract
of marine ﬁsh, showed a prebiotic in vitro activity, stimulating
probiotics (e.g., biﬁdobacteria; Hongpattarakere et al., 2012).
A β-D-(1−→4) with 1:2 β-D-(1−→6) branched glucan
produced by an isolated Chinese Rhizobium showed
immunopotentiating and antitumor activities in mice with
sarcoma 180 (S180), hepatoma 22 (H22) and Ehrlich ascites
carcinoma (EAC; Zhao et al., 2010).
Bioactive xanthan derivative
Xanthouronan, obtained by C-6 oxidation of xanthan with a
NaOCl/NaBr/TEMPO catalyst, exhibited in vitro antioxidant
activity (Delattre et al., 2015).
Hetero-EPS produced by nature isolated Enterobacter bacteria
strains, composed of fucose, glucose, galactose, glucuronic acid,
pyruvate, succinate, acetate (Freitas et al., 2011b; Huang et al.,
2015) showed hypoglycemic and hypolipidemic activities in type
2 diabetic mice (Huang et al., 2015). The signaling pathways of
action and the corresponding biomarkers – still under study –
are probably similar to plant extraction active polysaccharides.
Levans represent an EPS group of β-(2−→6)-D-fructans
with some β-(2−→1)-branches synthetized from sucrose by
levansucrase, produced by several bacteria, including species
of Bacillus, Zymomonas, Halomonas, Pseudomonas, Rahnella,
Aerobacter, Erwinia, Streptococcus,Microbacterium (Freitas et al.,
2011a; Esawy et al., 2012; Öner, 2013; Srikanth et al., 2015).
The levan produced by aHalomonas smyrnensis strain, especially
its oxidized (aldehyde) derivative, showed in vitro anti-cancer
activity against human lung (A549), liver (Hep G2/C3A), gastric
(AGS), breast (MCF-7) cancer cell lines (Sarilmiser and Öner,
2014). Acetyl, phosphoryl, and benzyl esters of levan EPS,
produced by a strain of Paenibacillus polymyxa, exhibited
antioxidant and anti-proliferative activities against human gastric
BGC-823 cancer cells in vitro (Liu et al., 2012; Zong et al.,
2012). The levan produced by Bacillus licheniformis exhibited
hypoglycemic and antioxidant activities, enhanced enzymatic
defense, protecting the main organs in alloxan-induced diabetic
rats (Dahech et al., 2011). The levans produced by honey
isolated Bacillus subtilis strains showed antiviral activity on avian
inﬂuenza and type 40 adenovirus (Esawy et al., 2012). The anti-
AIDS activity of levan was also noticed (Srikanth et al., 2015).
Antiviral activity, enhanced by sulfation, of other bacterial
EPS, was also noticed earlier (Matsuda et al., 1999; Laroche and
Michaud, 2007), as due to the interference with viral attachment
and penetration/infection of cells, probably by interacting with
viral envelope glycoproteins. Recent results, obtained by surface
plasmon response technology, conﬁrmed the interaction, curdlan
sulfate binding the recombinant human hepatitis B viral protein,
with increased aﬃnity toward the sulfation degree (Li et al., 2014).
Perspectives/Conclusion
Microbial EPS oﬀer a very large ﬁeld of medical applications,
increasingly exploited, yet at a too slow rate, if considering
their obvious advantages, some of them induced by their unique
properties.
As to the solid dosage forms and rate-controlled release
systems, they compete with cheaper natural polymers, as plant
cellulose and starch derivatives, speciﬁc niches (intelligent
therapeutics) being still to be established, along with their cost-
eﬀectiveness, by means of new, performant technologies.
As drug-targeting and carriers, EPS nanoparticulate systems
present certain advantages over those of chemical synthetic
origin, such as biocompatibility and apparent lack of toxicity.
However, they are not excluded from the mandatory non-clinical
pharmacotoxicology studies, as the chemical modiﬁcations
undergone by natural EPS still have to be carefully analyzed.
In this stage of research, the most important challenge,
common to all nanopharmaceuticals, is to demonstrate their
in vivo bioavailability for assuring a suitable drug exposure,
by passing from the discovered particular eﬀects to well-
established research protocols of absorption, distribution,
metabolism and elimination (ADME), drug metabolism and
pharmacokinetics (DMPKs). In this respect, recent developments
in EPS nanoparticle medical imaging systems could be very
useful, having also higher chances to be approved as diagnostics.
Obviously, based on all the above-mentioned considerations, the
external administration forms with topic action (e.g., wound
healing, skin-repair) are likely to be more rapidly approved for
and to pass clinical trials, as well as to enter the market, followed
by EPS-nanopharmaceuticals which have already shown in vivo
promising results, as well as by those which avoid the digestive
way (e.g., transdermal, nasal).
The EPS nanoparticulate systems should exploit some of their
advantages over liposomes (e.g., higher stability and versatile
functionalization), which have already advanced in approval of
clinical trials. More research eﬀort in speciﬁc challenging areas
of high interest, e.g., brain-targeting in neurological disorders
(stroke, tumors, Alzheimer’s), is expected.
Regarding bioactive EPS as potential therapeutics, their
challenge is to prove, necessarily in vivo, therapeutic advantages
over the drugs available on the market, and to observe the above-
mentioned well-established protocols for new drugs. Research
on associative formulations with already known therapeutics for
synergetic eﬀects should be also considered. New studies on the
molecular biology mechanisms of action will highlight structure-
activity relationships.
Nevertheless, the important therapeutic domains having
recorded promising results (e.g., cancer, diabetes, vaccines) still
expect further intense world-wide research work and a higher
involvement of microbial EPS in health improving resources.
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